Sangamo Therapeutics files for Chapter 11 bankruptcy; enters stalking horse asset sales to Lilly and Astellas

SANGAMO THERAPEUTICS, INC

• Filed voluntary Chapter 11 petition on June 23, 2026; stock suspended from Nasdaq on May 5, 2026, now trades on OTCQB.
• Entered stalking horse APA with Lilly for $50M to sell technology platforms including STAC-BBB, zinc finger, Modular Integrase, and prion program.
• Entered stalking horse APA with Astellas for $25M upfront plus up to $25M milestones for Fabry disease candidate isaralgagene civaparvovec.
• Obtained $30M DIP financing commitment from Northridge ATM, LLC to fund post-petition operations, subject to court approval.
• Board approved restructuring eliminating ~51 roles (~40% of workforce); expects $3-4M severance costs; retaining 77 employees.